<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>IVABRADINE</b></p>

<p><b>See also: bradycardia inducing drugs</b></p>

<p><b>From the French ANSM drug interactions document of </b></p>

<p><b>September 2016, pp. 136-137</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>IVABRADINE</b></p>

<p><b>RxNorm: 77417</b></p>

<p><b>ATC: C01EB17</b></p></td>
<td valign="top"><p><b>ANTICONVULSANT ENZYMATIC INDUCERS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>N03A-001</b></p></td>
<td valign="top"><p>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer</p>

<p>.</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of these substances together and after the inducer is stopped<b>. </b></p></td>
</tr>

<tr>
<td valign="top"><p><b>IVABRADINE</b></p>

<p><b>RxNorm: 77417</b></p>

<p><b>ATC: C01EB17</b></p></td>
<td valign="top"><p><b>AZITHROMYCIN </b></p>

<p><b>RxNorm: 18631 </b></p>

<p><b>ATC: J01FA10</b></p></td>
<td valign="top"><p>Increased risk of ventricular arrhythmias, especially of torsades de pointes. In addition, increase of the plasma concentrations of the ivabradine due to decrease of its metabolism by the azithromycin</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring and EKG during the administration of these substances together. </p></td>
</tr>

<tr>
<td valign="top"><p><b>IVABRADINE</b></p>

<p><b>RxNorm: 77417</b></p>

<p><b>ATC: C01EB17</b></p></td>
<td valign="top"><p><b>DILTIAZEM</b></p>

<p><b>RxNorm: 3443</b></p>

<p><b>ATC: C08DB01</b></p></td>
<td valign="top"><p>Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>IVABRADINE</b></p>

<p><b>RxNorm: 77417</b></p>

<p><b>ATC: C01EB17</b></p></td>
<td valign="top"><p><b>STRONG INHIBITORS OF CYP3A4</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>J02-J05</b></p></td>
<td valign="top"><p>Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>IVABRADINE</b></p>

<p><b>RxNorm: 77417</b></p>

<p><b>ATC: C01EB17</b></p></td>
<td valign="top"><p><b>JOSAMYCIN</b></p>

<p><b>RxNorm: 6084 </b></p>

<p><b>ATC: J01FA07</b></p></td>
<td valign="top"><p>Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>IVABRADINE</b></p>

<p><b>RxNorm: 77417</b></p>

<p><b>ATC: C01EB17</b></p></td>
<td valign="top"><p><b>ST JOHNS WORT</b></p>

<p><b>Hypericum perforatum</b></p>

<p><b>RxNorm: 258326</b></p>

<p><b>ATC: not found</b></p></td>
<td valign="top"><p>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the St Johns wort</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>IVABRADINE</b></p>

<p><b>RxNorm: 77417</b></p>

<p><b>ATC: C01EB17</b></p></td>
<td valign="top"><p><b>GRAPEFRUIT (JUICE AND FRUIT)</b></p></td>
<td valign="top"><p>Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit).</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>IVABRADINE</b></p>

<p><b>RxNorm: 77417</b></p>

<p><b>ATC: C01EB17</b></p></td>
<td valign="top"><p><b>RIFAMPICIN</b></p>

<p><b>RxNorm: 9384 </b></p>

<p><b>ATC: J04AB02</b></p></td>
<td valign="top"><p>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin </p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.</p></td>
</tr>

<tr>
<td valign="top"><p><b>IVABRADINE</b></p>

<p><b>RxNorm: 77417</b></p>

<p><b>ATC: C01EB17</b></p></td>
<td valign="top"><p><b>VERAPAMIL</b></p>

<p><b>RxNorm: 11170 </b></p>

<p><b>ATC: C08DA01 </b></p></td>
<td valign="top"><p>Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

</tbody>
</table>

